Global Cardiac Valve Market, By Treatment (Cardiac Valve Repair, and Cardiac Valve Replacement), Type (Mechanical Valves, Tissue/Bioprosthetic Valves, Transcatheter Heart Valves/ Percutaneous Heart Valves, and Others), Position (Mitral Valve Aortic Valve, and Other Position), End-User (Hospital and Clinics, Specialty Centers, Cardiac Research Institute, and Others) – Industry Trends and Forecast to 2031.
Cardiac Valve Market Analysis and Size
Valve replacement surgery is a pivotal application within the cardiac valve market, crucial for treating severe valve diseases where the natural valve is damaged or dysfunctional. This surgical procedure involves replacing the affected heart valve with either a mechanical valve made of durable materials such as metal or a biological valve derived from animal tissue or human donors. The choice between mechanical and biological valves depends on factors such as age, lifestyle, and medical history of the patient. Cardiac valve surgery aims to restore proper blood flow through the heart, alleviate symptoms such as shortness of breath and fatigue, and improve overall heart function, thereby enhancing the patient's quality of life and reducing mortality associated with severe valve diseases.
The global cardiac valve market size was valued at USD 11.34 billion in 2023 and is projected to reach USD 27.09 billion by 2031, with a CAGR of 11.5% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Cardiac Valve Repair, Cardiac Valve Replacement), Type (Mechanical Valves, Tissue/Bioprosthetic Valves, Transcatheter Heart Valves/ Percutaneous Heart Valves, Others), Position (Mitral Valve Aortic Valve, Other Position), End-User (Hospital and Clinics, Specialty Centers, Cardiac Research Institute, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Medtronic (Ireland), LivaNova PLC (U.K), Abbott (U.S), Colibri Heart Valve (U.S), On-X Life Technologies Inc. (U.S), TTK (India), JenaValve Technology Inc. (U.S), CryoLife Inc (U.S), Boston Scientific Corporation (U.S), Edwards Lifesciences Corporation (U.S), Symetis (Switzerland), Lepu Medical Technology(Beijing)Co.,Ltd. (China), Braile Biomédica (Brazil), Micro Interventional Devices, Incorporated (U.S), Auto Tissue Berlin GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
Cardiac valves are structures within the heart that regulate blood flow by opening and closing to ensure blood moves in the correct direction. There are four main valves in the heart: the mitral valve, tricuspid valve, aortic valve, and pulmonary valve. These valves open to allow blood to pass through and close to prevent backflow, maintaining efficient circulation throughout the body. Dysfunction or disease of these valves can lead to serious cardiovascular conditions necessitating medical intervention.
Cardiac Valve Market Dynamics
Drivers
- Growing Prevalence of Lifestyle Diseases
The prevalence of lifestyle diseases such as obesity, diabetes, and hypertension contribute to the development and progression of cardiovascular diseases, including valve disorders, which often necessitate surgical interventions such as valve replacement or repair. Lifestyle factors such as unhealthy diets, physical inactivity, and stress contribute to the rising incidence of these diseases globally. As these lifestyle-related risk factors continue to affect a larger segment of the population, the demand for cardiac valve surgeries and related treatments is expected to increase.
- Increasing Aging Population
Aging population is more prone to developing heart valve diseases such as aortic stenosis and mitral regurgitation due to wear and tear on the heart valves over time. This demographic trend results in a higher prevalence of valve disorders, necessitating surgical interventions such as valve replacement or repair. The growing number of elderly individuals seeking medical care for these conditions creates a substantial demand for cardiac valve procedures and related technologies. Consequently, healthcare providers and medical device manufacturers are focusing more resources on developing innovative treatments and improving surgical outcomes to meet the rising needs of this demographic group.
Opportunities
- Increasing Technological Advancements
Innovations in valve materials, such as bioabsorbable polymers and tissue-engineered valves, offer durable and biocompatible alternatives to traditional prosthetics. Moreover, advancements in imaging technologies, such as 3D echocardiography and cardiac MRI, enhance pre-operative planning and intraoperative guidance, leading to more precise surgeries and reduced complications. Minimally invasive techniques, such as transcatheter valve replacement (TAVR), have also revolutionized treatment by offering less invasive options for high-risk patients, reducing recovery times and hospital stays. These technological strides expand treatment possibilities and contribute to the overall growth and evolution of the cardiac valve market globally.
- Rising Healthcare Expenditure
Increased investment in healthcare infrastructure and services allows for greater accessibility to advanced cardiac treatments, including valve replacement surgeries. This financial support enables hospitals and healthcare facilities to procure state-of-the-art equipment, employ skilled medical professionals, and offer comprehensive cardiac care to a larger patient population. Higher healthcare spending fosters research and development in cardiovascular medicine, leading to innovations in valve technologies and surgical techniques. As economies grow and healthcare budgets expand, patients benefit from improved treatment outcomes and reduced mortality rates associated with cardiac valve diseases, reinforcing the market's growth trajectory.
Restraints/Challenges
- High Cost of Cardiac Valve Procedures
Valve replacement surgeries, whether using mechanical or biological valves, involve substantial expenses related to hospitalization, surgical equipment, anesthesia, and post-operative care. These costs can be prohibitive for patients without adequate insurance coverage or in regions with limited healthcare funding. Additionally, the pricing of prosthetic valves themselves contributes to the overall expense, particularly for newer technologies or biocompatible materials. High procedural costs may deter patients from seeking timely treatment or opting for alternative, less costly management strategies, impacting market demand and growth potential.
- Alternative Treatment Options
Alternative treatment options for less severe valve disorders or patients unwilling or unable to undergo surgical interventions. These alternatives include medication to manage symptoms such as blood thinners or medications to reduce blood pressure, as well as lifestyle modifications such as diet and exercise changes. Non-surgical procedures such as valvuloplasty (balloon valvuloplasty) offer a less invasive option for some patients but may not provide a permanent solution compared to surgical valve replacement. The availability and effectiveness of these alternatives can reduce the demand for surgical interventions, impacting the growth potential of the cardiac valve market.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In September 2019, Medtronic launched the Evolut PRO+ transcatheter aortic valve replacement (TAVR) system in the U.S. TAVR is a minimally invasive procedure used to treat severe aortic stenosis in patients who are at high risk for traditional open-heart surgery. The Evolut PRO+ system builds upon previous generations with enhanced features aimed at improving valve performance and patient outcomes, expanding treatment options for individuals with severe aortic valve disease
- In September 2019, Abbott initiated the TRILUMINATE pivotal trial for its TriClip transcatheter tricuspid valve repair system. This system is designed to address tricuspid regurgitation, a condition where blood flows backward into the right atrium due to improper closure of the tricuspid valve. The TriClip procedure aims to reduce regurgitation and improve heart function without the need for open-heart surgery, offering a less invasive treatment option for patients suffering from this challenging valve disorder
Cardiac Valve Market Scope
The market is segmented on the basis of type, treatment, position and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Cardiac Valve Repair
- Cardiac Valve Replacement
Position
- Mitral Valve
- Aortic Valve
- Other Position
Type
- Trans-Catheter Heart Valve
- Tissue Heart Valve
- Mechanical Heart Valve
- Others
End-user
- Cardiac Research Institute
- Hospital and Clinics
- Speciality centers
- Others
Cardiac Valve Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, type, treatment, position and end-user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America.
North America dominates the market due to its high incidence of cardiac disorders, bolstered by widespread adoption of advanced cardiac devices. The region benefits from robust healthcare infrastructure, facilitating early diagnosis and treatment. These factors contribute to a greater demand for cardiac valves, which are crucial in managing and treating various cardiac conditions prevalent in the population. Consequently, North America remains at the forefront of innovation and market growth in the cardiac valve sector.
Asia-Pacific is expected to experience significant growth in the market due to increasing elderly population, leading to higher demand for healthcare services and products. Additionally, changing lifestyles, characterized by rising incidences of chronic diseases, contribute to the healthcare sector's expansion. Moreover, the region is becoming a hub for medical tourism, attracting patients from around the world seeking affordable and high-quality healthcare services. These dynamics position Asia-Pacific as a pivotal region for healthcare growth in the coming years.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Cardiac Valve Market Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Medtronic (Ireland)
- LivaNova PLC (U.K)
- Abbott (U.S)
- Colibri Heart Valve (U.S)
- On-X Life Technologies Inc. (U.S)
- TTK (Chennai)
- JenaValve Technology Inc. (U.S)
- CryoLife Inc (U.S)
- Boston Scientific Corporation (U.S)
- Edwards Lifesciences Corporation (U.S)
- Symetis (Switzerland)
- Lepu Medical Technology(Beijing)Co.,Ltd. (China)
- Braile Biomédica (Brazil)
- Micro Interventional Devices, Incorporated (U.S)
- Auto Tissue Berlin GmbH (Germany)
SKU-